Defining Mutations of DNA Repair Genes in Prostate Cancer Patients Towards Enhancing Treatment
Abstract
DNA damage repair genes (DDRGs) are critical for protecting genome integrity and have been implicated in several cancer types. Recent genomic studies of metastatic castration resistant prostate cancer (mCRPC) highlight the contributions from mutations or copy number changes in DDRG alterations, including BRCA1, BRCA1, ATM, CHEK2, and MSH2. It has also been shown that prostate cancer (CaP) patients harboring inherited mutations in DDRGs may benefit from early targeted PARP inhibitor therapy. However, the association of germline mutations of DDRGs with earlier stage high risk CaP patients remains to be defined. Accumulating evidence suggest for increased association of BRCA2 mutations with more aggressive CaP. Our recent data show an association of increased frequency of BRCA2 gene mutations in CaP patients with African ancestry with elevated risk of developing metastasis. We hypothesize that AA CaP patients have an increased frequency of mutated DDRGs.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2018
- Accession Number
- AD1057039
Entities
People
- Shiv Srivastava
Organizations
- Henry M. Jackson Foundation for the Advancement of Military Medicine